CLUN19153, Mulford, EA5163/S1709, NSCLC, Carboplatin, Pemetrexed
Research Question:
Is pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin
with or without pembrolizumab after disease progression, superior to induction with
pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed
maintenance in treating patients with stage IV non-squamous non-small cell lung cancer?
Basic Study Information
Purpose:
This phase III trial studies whether pembrolizumab alone as a first-line treatment,
followed by pemetrexed and carboplatin with or without pembrolizumab after disease
progression is superior to induction with pembrolizumab, pemetrexed and carboplatin
followed by pembrolizumab and pemetrexed maintenance in treating patients with stage
IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies,
such as pembrolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. It is not yet known whether giving first-line pembrolizumab followed
by pemetrexed and carboplatin with or without pembrolizumab works better in treating
patients with non-squamous non-small cell cancer.
Location: University of Rochester Medical Center
Study Reference #: CLUN19153
Lead Researcher (Principal Investigator)
Lead Researcher:
Megan Baumgart
Study Contact Information
Study Coordinator: Nichole Ransom
Phone: +1 585-276-8747
Email: nichole_ransom@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search